New pill for chronic hives enters first human safety tests

NCT ID NCT07540910

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests the safety of an experimental oral drug called EDP-978 in 98 healthy adults. Researchers will give single and multiple doses to see how the body handles it and whether it causes side effects. The drug is being developed for chronic hives, but this study does not test if it works—only if it is safe enough to study further.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

EDP-978

What this could lead to

If safe, this could lead to larger trials testing EDP-978 as a treatment for chronic hives.

What could go wrong

This is a very early, small study in healthy people, not patients. It only checks safety and dosing, not whether the drug works for hives.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic idiopathic urticaria chronic inducible urticaria Chronic Urticaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • ICON Early Phase

    RECRUITING

    San Antonio, Texas, 78209, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Email: •••••@•••••